Price-to-earnings: BT vs. RX

Biotech's average P/E ended 1Q at 20.8, down 14% from 4Q15 and 17% from a year ago. Two companies - rare disease play Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and neurology and immunology company UC...